News

Video: Principal Investigator Experience and Engagement

About half of Principal Investigators (PIs) conduct only a single study in their career. This high turnover rate results in significant inefficiencies for Sponsors and CROs, particularly when it comes to finding reliable PIs capable of delivering high-quality trial conduct and enrollment in specialized research areas.

Velocity developed the innovative Principal Investigator Onboarding and Training (PIVOT) Program to address the pressing issue of “one-and-done” PIs in clinical research. This strategic initiative equips new PIs with comprehensive knowledge, tools, infrastructure, and mentorship opportunities.

The PIVOT Program:

  • Elevates PI engagement, performance, and retention through a novel curriculum
  • Combines industry leading training content, hands-on experiences, and mentorship
  • Specific training tracks for full-time PIs and specialist PIs with embedded operations

Learn more at https://velocityclinical.com/investigator-expertise

Velocity Joins the IQVIA Connected Research Community in Europe

Velocity is proud to be a part of IQVIA’s Prime and Partner Site Programme. IQVIA have created a joint innovation group with representatives from their elite network of Prime and Super Partner sites across Europe, known as the “IQVIA Connected Research Community”. The purpose is to share ideas, lessons-learned, challenges, and innovations across our sites and … Read more

Video: Community Engagement

To bring equitable products to market, clinical trials need proportionate representation. Reaching the right patients must be prioritized at the site level, where clinical research is most visible in communities. Therefore, Velocity is heavily invested in leveraging the power of local influence to drive change. Our focus is on managing what we can effectively control … Read more

Julio Rosenstock, MD, FACE, Co-Authored an Article Published in Cardiovascular Diabetology

Julio Rosenstock, MD, FACE, is an author of an article published yesterday in Cardiovascular Diabetology. Using baseline characteristics of study participants from an ongoing trial, researchers identified clinical characteristics of individuals with type 2 diabetes and features of stage B heart failure that may help clarify the diagnosis of diabetic cardiomyopathy (DbCM) in clinical practice. Read … Read more

Video: Environmental Governance

As Nicholas Campbell explains, good business can also be good for the environment. As Velocity improves lives by accelerating the development of new therapies, we can also build a healthier tomorrow by conducting trials in a sustainable way. How can Velocity deliver more efficient trials? Enhanced site enrollment forecasting to minimize overages, alongside reduced investigational product distribution … Read more

Julio Rosenstock, MD, FACE, Lead Author Published in OUP Endocrine Reviews Article

Julio Rosenstock, MD, FACE, is the lead author of an article published today in the Oxford University Press’ Endocrine Reviews Journal. Reviewing data from Phase 2 clinical trials for basal insulins icodec and efsitora, as well as the Phase 3 icodec program, the article indicates that once-weekly insulins provide comparable glycemic control to once-daily analogues, with a … Read more

Video: Demand and Delivery

Watch Christy Godwin and Laura Falcone discuss Velocity’s unique ‘Demand and Delivery’ approach. Christy and Laura work in unison to ensure full alignment among what Sponsors and CROs demand, and the quality, performance, and patient experiences Velocity delivers. In this video, they delve into: The importance of understanding goals and translating them into actionable strategies … Read more

Velocity Transforms Patient Experience and Recruitment With VISION Technology Platform

Velocity Clinical Research, the leading multi-specialty clinical sites business, has launched its VISION technology platform to transform the way patients access and participate in clinical trials.  Velocity’s VISION technology unifies patient experience and recruitment capabilities across nearly 100 locations globally. The AI-driven platform includes VISION Engage, a patient-focused mobile application that has had 30,000 downloads … Read more

Video: Scale for a Purpose

A staggering 80% of clinical trials are delayed or shut down due to enrollment challenges, with half of those delays occurring at the site level. Two-thirds of principal investigators leave research after conducting a single trial. It’s time for a change. Watch Paul Evans, Nick Campbell, Nick Spittal, and Craig Koch discuss Velocity’s unique model, … Read more